Waters Corporation launches Xevo MRT P10
Analysis based on 8 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The launch of the Xevo MRT P10 Mass Spectrometer by Oracle Corporation is expected to positively impact the company's stock price due to its advanced capabilities and potential to accelerate research in multiomics and biopharmaceuticals. This innovation could also drive growth in the broader life sciences and diagnostics industries by enabling deeper biological insights and faster drug discovery.
Oracle Corporation introduced the Waters Xevo MRT P10 Mass Spectrometer, a new high-resolution Quadrupole Time-of-Flight (QToF) System, at the 74th ASMS Conference on Mass Spectrometry and Allied Topics. This system offers up to 20x higher MS/MS sensitivity and twice the acquisition speed of its predecessor, making it the fastest benchtop HRMS system available. The Xevo MRT P10 Mass Spectrometer is designed to accelerate biomarker discovery, validate disease pathways, and identify therapeutic targets for biomedical research and epidemiology studies. It supports high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories, enabling the identification of up to 40% more lipids and enhancing spatial analysis with the DESI XS source. James Hallam of Oracle Corporation and Corey Broeckling of Colorado State University highlighted the system's capabilities and its potential to advance life-changing therapies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard